Acute myeloid leukaemia (AML) is characterized by specific cytogenetic aberrations that are strong determinants of prognostic outcome and therapeutic response. Because the pathological outcome of AML patients with cytogenetic abnormalities differs considerably, we hypothesized that their proteome may also differ specifically in their expression pattern, protein interaction pathways and post-translational modifications (PTM). We performed this study using 42 AML patients diagnosed for various cytogenetic abnormalities based on two-dimensional gel electrophoresis and matrix-assisted laser desorption/ionization time of flight mass spectrometry (MS) and MSMS tandem MS. We could identify significant differences in the proteome and PTM of peptides, later confirmed by other methods, between cytogenetic groups. The interactome analysis based on computational bioinformatics reveals major regulating networks: MAPK8 and MYC for complex aberrant karyotype, TP53 for t(8;21), TP53-MYC-PRKAC for 11q23 and JUN and MYC for Inv(16). Further, we analysed 42 MS spectra representative of hnRNPH1, calreticulin and hnRNPA2/B1 in a peak explorer, which reveals a cytogenetic-specific PTM of b-O-linked N-acetyl glucosamine (O-GlcNAc) of hnRNPH1 in AML patients with 11q23 translocation, an acetylation of calreticulin in t(8;21) translocation and methylation of hnRNPA2/B1 in patients with translocations of t(8;21) and inv(16). This report may lead to a new thinking about AML pathogenesis, as differences at PTM level could be used to distinguish different subtypes of AML.
Introduction
One of the important features of acute myeloid leukaemia (AML) is the occurrence of cytogenetic abnormalities. Cytogenetics is strongly predictive of response to induction and consolidation therapy for AML (Marcucci et al., 2004) . The cytogenetic abnormalities involving translocations of t(8;21), t(15;17) or inv(16) are associated with favourable prognosis (Grimwade et al., 1998) . The group of AML that is characterized by aberrations of chromosomes 5 and 7 or abnormalities of 11q23 shows a poor response to chemotherapy (Schoch et al., 2005) . Finally, there is a heterogeneous group of patients who do not show any apparent cytogenetic aberrations. This group is considered an intermediate AML risk group (Bienz et al., 2005) . Refinements in the diagnosis of cytogenetic abnormalities of AML and advances in the therapeutic approaches have improved the outcome for patients with AML. However, the survival rate among AML patients is only 30%, which demands new findings that promise to improve cure rate. Recent advances in gene expression profiling using oligo c-DNA microarray have been used to differentiate cytogenetic groups and to identify new subgroups within the intermediate risk group of AML with normal karyotype (Bullinger et al., 2004) . Even though transcriptomics provides relevant information regarding gene activity and cell function, however, they do not necessarily correlate with levels of protein expression, and such analysis cannot detect important post-translational modifications of proteins (PTMs), such as acetylation, phosphorylation or glycosylation. Proteomics has emerged as an indispensable technique to identify the proteome and PTMs, which indeed represent a functional state of a cell, thereby offering an understanding of physiological and pathological state of a cell. The identified proteome leads to new way of understanding the biological interaction in determining the disease relevant pathways for the primary drug targets (Cristea et al., 2004) . This study provides a platform for distinguishing AML cytogenetic subgroups according to their protein expression pattern and MS peak pattern corresponding to PTM differences. This might improve our ability to understand the molecular differences between AML cytogenetic subgroups and would be precisely used for designing subtype-specific therapies.
Results
Mass spectrometry-based identification of proteins from different AML cytogenetic groups This investigation was performed on 42 AML patients belonging to different cytogenetic groups after obtaining their written consent. Table 1 represents the patients used in the study with their cytogenetic characteristics; full karyotype details can be requested from the authors. MLL(11q23) has been characterized as a specific subtype of AML (Haferlach et al., 2004) . This is in accordance with the latest WHO classification of AML where cytogenetics abnormalities have been used as a major criterion. The proteins were determined by matrix-assisted laser desorption/ionization (MALDI)-time of flight (TOF) mass spectrometry (MS) and MS-MS analysis. From the silver-stained two-dimensional Table 2 ). This statistics points towards the fact that each cytogenetic translocation contributes significantly to the altered proteome. Details of all the identified proteins are given in Supplementary Table 1 .
Proteins identified as distinguished targets of AML cytogenetic groups
We could identify a set of proteins from each cytogenetic group and a normal karyotype subtype, which are distinguishing features of each AML subtype. Table 2 gives the details of these proteins including the known sites of S/T/Y phosphorylation for some of the proteins; full image 2D gels with the spot position from these proteins are given in Supplementary Figure 1 . The expression pattern of myeloperoxidase variant H17, sorcin, B-cell CLL/lymphoma 11A and transcription factor MafK, identified from t(15;17), t(8;21), CK and Inv(16) , respectively, showed a distinct identification in comparison to other AML cytogenetic groups, normal karyotype and CD34 þ cells. Even though we could reproduce the 2D pattern from other subtypes, healthy bone marrow and human CD34 þ cells, we could not identify these proteins from the rest of other subtypes ( Figure 1A) . The corresponding spot positions in the controlled gels, linear range pH 3-10, were consistently absent from other subtypes. These proteins may serve as an important marker for prognosis and pathogenesis previously unknown for cytogenetic groups of AML.
Validation of differential expression of hnRNPA2/B1, casein kinase 1 alpha, prohibitin, HSC70 and apoptosis inhibitor survivin We performed Western blot analysis to confirm the proteome findings of some of the potential therapeutic and prognostic marker proteins previously not implicated in AML. Casein kinase 1 alpha previously identified by mass spectrometry in normal karyotype patients showed an elevated and distinguished expression in three different NK patient samples in immunoblots (Figure 2, a and b) . We showed a differential expression of RNA-binding protein hnRNPA2/B1 in NK patients (panel c). This was further confirmed from three different NK patients (panel d). K562 erythroleukaemic cell line lysate was used as a positive control for the expression of hnRNPA2/B1. In a similar analysis, we could show a differential expression of cell cycle protein prohibitin in t(8;21) and Inv(16) patients ( Figure 2 ). Separate subnetworks for each cytogenetic group were generated; subnetworks from each AML subgroup were merged to obtain a wider network of interactions. The major regulating network and the signalling pathways contributed by these networks appeared to be MAPK8 and MYC for complex aberrant karyotype, JUN and MYC for Inv(16), TP53 for t(8;21) and TP53, MYC and PRKAC (cAMP-dependant kinase) for 11q23 ( Figure 2 , a-c and d). We identified different hyperactive modules in the networks by singling out those proteins that, by a Proteomweaver analysis, expressed the highest mean expression value in Proteomics of acute myeloid leukaemia MY Balkhi et al a network indicated by red colour intensity of a node (highlighted modules in Figure 2 ). In a complex aberrant karyotype, a module comprised of HDAC, E2F, TP53 and RBL2 is activated in the signature network of CK (panel a). Similarly, in a signature network of Inv (16), serine (or cysteine) proteinase inhibitor (SERPINB1) is highly upregulated (mean spot intensity of 2.412 is highest in the network (refer Figure 2 , b). The module comprised of transcription factors C/EBPalpha (CEBPA), C-MYB and proteinase 3 (PRTN3) may be a dysregulated module, which is more likely the case as C/EBPalpha is mutated in 10% of all AML cases. Similarly, for t(8;21) a module comprised of transcription elongation factor A (TCEA1) and FOS which belongs to the family of AP1 transcription factors, appeared to be hyperactive. Interestingly, the activated modules appear to be different in each cytogenetic group.
Cytogenetic groups showed significant differences in their protein expression patterns The proteins identified as common targets of various cytogenetic groups, which contribute to 65% of all proteome identified, showed a significant quantitative variation in their expression pattern. For a comparison of a set of spot intensities of different gels from different AML cytogenetic groups, the standard deviation of a matched spot was estimated. We could identify significant differences of some of the proteins identified from various cytogenetic groups, normal karyotype, CD34 . This comprises the peptide region between I186K206. The peptide has only one C-terminal lysine residue, K206, that could serve as the site for acetylation. The Peptide Cutter theoretical digestion database (http//prospector. ucsf.edu) (Lominadze et al., 2005) revealed the presence of another ion (m/z) 2391 with the same sequence as that of 2433 ion. We suspect it to be the acetylated peptide, which is shifted by 42 Da from a peptide (m/z) 2391. The reanalysis in a peak explorer for calreticulin 
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MS spectra identified from t(8;21) discovered the acetylated peak (m/z) 2433 to be present ( Figure 5 , a and b). However, the similar procedure followed for MS spectra of calreticulin in other subtypes like t(15;17), complex karyotype, Inv(16) and normal karyotype could not detect the acetylated peptide even though the peak (m/z) 2391 was present. This suggests that this modification is unique to t(8;21)-AML. Next we selected hnRNPH1, which is already known to be modified by alternative processing of pre-mRNA 
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splicing and by PTM (Wang et al., 2004) . We searched this protein within t(15;17), complex karyotype, 11q23 and t(8;21) AML cytogenetic groups for possible PTM. We analysed for hnRNP H1, two different MS spectra from t(15;17) patients, three spectra from 11q23, two spectra from complex aberrant and three spectra from normal karyotype. Unique to 11q23 patients, a high intense peak, 2044, was consistently found, which showed a difference of 203 Da from a genuine tryptic ion, 1841 ( Figure 6 ). This corresponds to the mass of O-linked acetyl hexosamine (O-GlcNAc) adduct, a modification covalently binding to hydroxyls of threonine or serine residues (Sagi et al., 2005) . However, further MS analysis of hnRNPH1 from other cytogenetic groups failed to show the presence of glycosylated (m/z) 2044 ion from the cytogenetic subgroups of t(15;17), t(5;6)del (9) (Figure 6d ). This confirms the site to be threonine 152. To further confirm the neutral losses of immonium and other ions, which should match for both the ions, we dissected the low (m/z) region and acquired a similar pattern (data not shown).
Further, we confirm the O-GlcNAc PTM by immunoblot analysis of whole-cell lysates from three different 11q23-positive patients using O-GlcNAc-specific antibody CTD110.6, which has been successfully used previously in immunoblots and ELISA, Supplementary Information, immunoblots and antibodies. We detected a signal for O-GlcNAcylation at 48 kDa, ( Figure 6B , panel a). In each of these experiments, the specificity of CTD110.6 immunoreactivity was established by competitively blocking antibody binding with free GlcNAc. The same gel was reprobed for hnRNPH; we could confirm the detection of hnRNPH (48 kDa) in the same region where GlcNAcylation was detected ( Figure 6B  panel b) .
In a further analysis, we investigated the methylation pattern of a protein hnRNPA2/B1 identified from various cytogenetic groups. We could identify hnRNPA2/B1 from NK, normal bone marrow, t(8;21) and Inv(16) patients. For hnRNPA2/B1, we analysed two MS spectra from t(8;21), one from 11q23 patient, one from normal bone marrow and four from normal karyotype. The representative MS spectra of this protein with tryptic ions are shown in Figure 7 . We investigated the spectra of hnRNPA2/B1 for methylation modification. We included methylation as a variable modification in a MASCOT search (data not shown); peptide cutter theoretical digestion database revealed ion (m/z) 1879 to be dimethylated. The detailed peak dissection of the real MS spectra of hnRNPA2/B1 discovered this peptide with a dimethylated signature with a sequence RGFGFVTFDDHDPVDK, a peptide region between R153K168 (Figure 7b-d) . Methylation occurs predominantly on arginine-and glycine-rich RGG residues (Li et al., 1998a; Lin et al., 2000) . This ion has an N-terminal R153G154 motif, which is the site of dimethylation, R Me G Me FGFVTFDDHDPVDK. The ion must have shifted by a 28 Da mass from (m/z) 1852. The detailed dissection across MS spectra of this protein revealed the presence of this ion, (Figure 7d ). The theoretical digestion database revealed this ion has the same sequence as that of 1879 ion (data not shown). A similar analysis for hnRNPA2/B1 failed to detect the dimethylated ion for NK patients (data not shown).
Discussion
The systematic investigation of molecular differences between various cytogenetic risk groups of AML has not been fully addressed. The present study involves the MS-based characterization of proteomics, bioinformatics and MS-based peak pattern analysis. Characterization of proteomic differences between sets of AML patients with balanced chromosomal translocations is crucial given that any observed variation in its expression pattern and peak pattern may have prognostic and disease relevance (Nedelkov et al., 2005) .
We could identify considerable differences in the proteome pattern, which may discriminate between cytogenetic risk groups, healthy bone marrow and CD34. The expression pattern of some of the proteins may correlate for diagnosis, prognosis and pathogenesis. The expression of hnRNPA2/B1 or casein kinase 1 alpha shows higher expression in NK patients in comparison to other subtypes where it is either less expressed or absent. This may mean a positive discriminatory diagnostic marker for NK patients. However, for many of the other proteins that we report here as showing discriminatory pattern of expression between AML cytogenetic groups, their clinical significance remains to be investigated. For example, transcription factor MafK, which we identified as a distinguished target of Inv(16), is known to promote the erythroid differentiation programme in erythroleukaemic cells and acts as a crucial regulator of many erythroid-specific genes (Igarashi et al., 1995) . B-cell CLL lymphoma/leukaemia 11A identified as a differential target of CK functions as a myeloid and B-cell proto-oncogene. Its high expression in AML points towards a probable role in leukemogenesis and haematopoiesis (Satterwhite et al., 2001 ). In our validation experiments, we detected the differential expression of IAP in t(8;21) patients and AML1/ETO-inducible system. This is a significant finding, as survivin has received great attention owing to its potential therapeutic target in cancer. It is noteworthy that overexpression of survivin leads to the dysregulation of spindle dynamics and stabilizes both actin and beta tubulin (Li et al., 1998b; Gurbuxani et al., 2005) . Mapping protein networks for various cytogenetic risk groups in vivo is critical for realizing the promise of subtypespecific patient-tailored molecular therapy. The proteins whose expression is significantly altered between cytogenetic groups could explore therapeutically relevant networks by providing an idea of dysregulation or hyperactivity in the network of intracellular signalling cascades (Petricoin et al., 2005) . We applied this approach by employing one of the publicly available databases for generating the protein interactions. Our results present cytogenetic-specific signature networks and hyperactive modules. This provides valuable information regarding the dysregulation of signalling pathways based on differential proteome data. Many proteins with oncogenic potential undergo a complex series of PTM. Identification of these modifications presents a formidable challenge, but their determination generates indispensable insights into disease progression and possible key therapeutic and prognostic targets (Mann and Jensen, 2003) . Information regarding the PTM differences that may correspond to prognosis, pathogenesis and therapeutically relevant targets has not been fully investigated in the context of cytogenetic risk groups of AML. We analysed the MS spectra of some of these commonly regulated proteins, which we could identify among all the cytogenetic groups, to look into possible differences in their MS spectra which may correspond to PTM differences. Generally, this information is overlooked in the majority of other highthroughput proteomic studies undertaken. For this analysis, we selected calreticulin, hnRNPH1 and hnRNPA2/B1. Here we show that calreticulin is modified by acetylation, specifically in t(8;21) AML. Increased calreticulin expression is correlated with the suppression of the granulocytic differentiation factor CEBPA in AML with inv(16) and t(8;21); calreticulin is also reported to interact with C/EBPalpha and C/EBPbeta mRNA and represses them at protein level (Helbling et al., 2004; Helbling et al., 2005) . AML patients positive for t(8;21) have undetectable C/EBP alpha protein as compared to other subgroups of AML patients (Timchenko et al., 1996 (Timchenko et al., , 2002 . These effects may be in part owing to the acetylation of calreticulin in t(8;21) which we reported here and not because of the nascent calreticulin protein alone.
hnRNPs are differentially regulated by alternative processing of pre-mRNA and by PTM. However, among AML cytogenetic subgroups, the significance at the post-translational level is unknown except for hnRNP p43, which is known to get modified by O-GlcNAc (Vosseller et al., 2001; Wells et al., 2003) . Here we could show that hnRNPH1 is reversibly modified by O-linked acetyl hexosamine (GlcNAc) in 11q23-positive patients. The covalent modification of intracellular proteins by O-GlcNAc is a crucial regulatory PTM which plays a role in apoptosis and modulates transcriptional and signal transduction events (Khidekel et al., 2004) , and may be associated with high therapeutic significance for AML in general and 11q23 translocations in particular.
Methylation pattern constitutes an important regulatory mechanism of large number of genes have been reported to be methylated in AML, and differences in the pattern of methylation have been reported between various subtypes of leukaemia (Wolffe and Matzke, 1999; Herman and Baylin, 2003) . The expression of hnRNPA2/B1 is a prognostic marker for early lung cancer detection (Zhou et al., 2001) . Interestingly, we report for the first time differences in the methylation pattern of hnRNPA2/B1 in AML patients. Interestingly, the intensity of this peptide in t(8;21) and Inv (16) is 10-and 20-fold higher than NBM (Figure 7) . Even though the technique in itself is not quantitative unless the peptides are tagged, however, growing the blasts in culture and tagging in vivo to accurately quantitate is the limitation to achieve this end. Nonetheless, the intensity value of methylated ion of hnRNPA2/B1 in t(8;21) and Inv(16) is in itself highly significant than NBM.
Our findings support the rational hypothesis that chromosomal translocations are associated with specific proteomes. AML, which is long believed to be heterogeneous in nature, differs at the basic biological set up and fusion proteins fundamentally alter the proteome. Furthermore, the detection of modified peptides by MS peak import analysis could provide new insights into the functional modulation of these disease relevant proteins.
Materials and methods

AML patient samples
Forty-two AML bone marrow samples of the following subtypes were used: t(8;21) (n ¼ 6), t(15;17) (n ¼ 7), inv(16) (n ¼ 6), 11q23 (MLL/PTD) (n ¼ 6), normal karyotype (n ¼ 11), complex aberrant karyotype (n ¼ 6). The studies were conducted according to the rules of the local ethical committee and the revised Helsinki protocol. Written informed consent from the patients was obtained. At the time each AML patient was diagnosed, mononuclear cells from the bone marrow aspirate with more than 90% blast cells were purified by Ficoll density centrifugation. The healthy bone marrow cells were purchased from stem cell technologies (cell systems Biotechnologie Vertrieb GmbH). CD34 þ cells were isolated from the remains of leukapheresis products and sorted by MACS by a positive selection using CD34 progenitor cell isolation kit, human, Miltenyi Biotech.
2DE and DIGE
Five master gels with gradients pH 3-10 and 4-7 were made from each cytogenetic group: t(8;21) (four gels pH 3-10 and one gel pH 4-7), t(15;17) (two gels pH 3-10 and three gels pH 4-7), Inv(16) (three gels pH 4-7 and two gels pH 3-10), complex aberrant karyotype (four gels pH 3-10), 11q23 (three gels pH 3-10) and normal karyotype (10 gels pH 3-10 and three gels pH 4-7), healthy bone marrow (two gels pH 3-10) and CD34 þ cells (two gels pH 4-7 and one gel pH 3-10). In order to control the gel-to-gel variability in staining and running conditions between cytogenetic groups, four patient samples belonging to different cytogenetic groups were processed together. In all the experiments, 300 mg of proteins was subjected to IEF and a minimum of four 2D gels were run and stained together. 10 7 cells from each patient sample were carefully thawed and dissolved in 10 ml of IMDM, supplemented with 20% FCS, heparin 200IE per ml and DNAse. After centrifugation, the pellet was lysed in a sample buffer containing 7 M urea, 2 M thiourea, 4% (w/v) 3-[(3-cholamidopropyl) dimethylammonio]-1-propanesulphonic acid (CHAPS) and 1% (w/v) DTT for all silver-stained gels. For DIGE experiments, samples were dissolved in a DIGE compatible lysis buffer containing 25 mM Tris, 4% CHAPS (w/v), 8 M urea and 2 M thiourea. Protein labelling with cyanine dyes (Cy3 or Cy5) was performed according to the manufacturer's (Amersham Biosciences) instructions. For all silver-stained gels and DIGE experiments 300 and 50 mgs of protein were used, respectively. The proteins were subjected to isoelectric focusing for the first dimension of protein separation, which was performed with a Multiphore II electrophoresis system (Amersham Biosciences, Piscataway, NJ, USA). Immobiline dry IPG strips (for DIGE: 24 cm, pH 4-7 linear IPG strips, Amersham Biosciences) were rehydrated overnight with the sample/rehydration buffer mixture. For silver staining 18 cm, pH 3-10 and 4-7 linear IPG strips were directly rehydrated with the sample buffer. The strips were subjected to electrophoresis using a ramping IPG strip (200-8000 V) focusing algorithm. After the isoelectric focusing, the gel strips were electrophoresed in vertical SDS-polyacrylamide gel electrophoresis (PAGE) gels containing 12.5% acrylamide. The Cy2, Cy3 and Cy5 gels were scanned at 473, 532 and 635 nm excitation laser filter using laser-based FUJI scanner (Fluor imager, FLA 5100 version 1.0).
Statistical analysis
For evaluating the mean expression volumes (mean intensity values) of in-gel spots, gels were matched from within a particular cytogenetic group and from other cytogenetic groups. Proteomweaver software, version 2.0, Definiens AG, Munich, was used. Standard statistical methods were used to analyse the plots including mean, standard deviation and coefficient of variation calculated as standard deviation/mean. Changes in spot intensity were considered significant where the average normalized volume altered by greater than 1.5-fold between samples. P-values were calculated from the Student's t-test by comparing the means of two different AML subtypes (expressed as the standard deviation of the difference between the two means).
MALDI-TOF MS
Spots were excised manually from silver-stained gels and for fluorescent gels an automatic spot picker (Bruker daltonic) was used. Gel pieces were rehydrated in 50 ng/ml trypsin (Promega, Southampton, UK) in 25 mM ammonium bicarbonate on ice for 20 min. The gel pieces were incubated at 371C overnight. The speedVac dried peptides were dissolved in 5 ml of 20% (v/v) acetonitrile and 0.1% (v/v) trifluoroacetic acid, sonicated for 5 min and spotted along with 0.5 ml of 10mg/ml a-cyano 4-hydroxycinnamic acid (CHCA, Sigma, Munich, Germany) in 50% (v/v) acetonitrile and 0.1% (v/v) trifluoroacetic acid onto a MALDI target plate for analysis. The mass determinations were performed on the MALDI TOF/TOF mass spectrometer (Applied Biosystems, Darmstadt, Germany, AB4700) operating in reflectron mode and with ion source pressure B0.5 mTorr. After a 400-ns time-delayed ion extraction period, the ions were accelerated to 20 kV for TOF mass spectrometric analysis. A total of 600-1000 laser shots were acquired and signal averaged. The data were analysed through GPS explorer (AB 4700 Inc., USA) using a Swiss/Prot protein database for Mascot search assuming (1) monoisotopic peptide masses, (2) cysteine carbamidomethylation, (3) variable oxidation of methionine, (4) a maximum of one missed trypsin cleavage and (5) a mass accuracy of 60 p.p.m. or better, minimum signal/noise 45. The four high intense peaks were selected in a range between m/z 1500 and 2500 for MS-MS peptide sequencing in an interpretation method. A molecular weight search (MOWSE) score >53 was assumed to indicate a significant match.
For detailed MS and MS-MS spectra analysis, the MS spectra of potential proteins to be dissected for possible PTMs were imported to the peak explorer software, and the MS-MS spectra were imported and sequenced in the data explorer software. The PTMs were included as a variable modification, and searched by MASCOT database. Further to narrow down MASCOT search, we created separate path for calreticulin, hnRNPH1 and hnRNPA2/B1 in MSDB. The modified peptides was reanalysed in a peak explorer from their corresponding MS spectra. For this analysis, we used all the MS spectra of calreticulin, hnRNPA2/B1 and hnRNP H identified from different subgroups. The sample corresponding to hnRNPH1 was fractionated by Nano LC (Dionex, Idstein, Germany) using 500 mm i.d. Â 5 mm, C18 reverse phase column with a flow rate of 200 nl/min.
